Related references
Note: Only part of the references are listed.In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study
K. J. Christiansen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa
Marc H. Scheetz et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates
Philip J. Turner
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients
Scott A. Van Wart et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2009)
Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients
Kazuro Ikawa et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections
Cristina Suarez et al.
JOURNAL OF INFECTION (2009)
Comparison of different methods of determining β-lactam susceptibility in clinical strains of Pseudomonas aeruginosa
Eva Torres et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2009)
Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites
Deniz Gur et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2008)
Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program
Volkan Korten et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling:: application to meropenem dosage and combination therapy
L. Santos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain:: a 5-year analysis
Alvaro Pascual et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2007)
Antimicrobial resistance surveillance:: VIRA STUDY 2006
Juan J. Picazo et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2006)
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation
BM Lomaestro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility
E Lesho et al.
CLINICAL INFECTIOUS DISEASES (2005)
Doripenem (S-4661), a novel carbapenem:: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations
RN Jones et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Share Paper
